Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR

Stem Cells

Volumn 15, Issue 6, 1997, Pages 398-408

  Plesner, T ^a,c   Behrendt, N ^b   Ploug, M ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b FINSEN LABORATORY   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Adhesion molecule; Differentiation antigen; Integrins; Myelopoiesis; Plasminogen activator; Urokinase; Urokinase type plasminogen activator receptor (uPAR); Vitronectin

Indexed keywords

ALPHA 2 ANTIPLASMIN; ENZYME PRECURSOR; INTEGRIN; LIGAND; MEMBRANE RECEPTOR; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROUROKINASE; UROKINASE; VITRONECTIN;

BINDING AFFINITY; BLOOD CELL; BONE MARROW CELL; CELL ADHESION; CELL INTERACTION; CELL MEMBRANE; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; LIGAND BINDING; NONHUMAN; PLASMINOGEN ACTIVATION; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0030782196     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.150398     Document Type: Review

References (113)

1. Vassalli JD, Baccino D, Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 1985;100:86-92.
2. Cubellis MV, Nolli ML, Cassani G et al. Binding of single-chain prourokinase to the urokinase receptor of human U937 cells. J Biol Chem 1986;261:15819-15822.
3. Nielsen LS, Kellerman GM, Behrendt N et al. A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification. J Biol Chem 1988;263:2358-2363.
4. Estreicher A, Wohlwend A, Belin D et al. Characterization of the cellular binding site for the urokinase-type plasminogen activator. J Biol Chem 1989;264:1180-1189.
5. Lund LR, Rønne E, Roldan AL et al. Urokinase receptor mRNA level and gene transcription are strongly and rapidly increased by phorbol myristate acetate in human monocytelike U937 cells. J Biol Chem 1991;266:5177-5181.
6. Picone R, Kajtaniak EL, Nielsen LS et al. Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate. J Cell Biol 1989;108:693-702.
7. Behrendt N, Rønne E, Ploug M et al. The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J Biol Chem 1990;265:6453-6460.
8. Behrendt N, Ploug M, Patthy L et al. The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J Biol Chem 1991;266:7842-7847.
9. Ploug M, Ellis V, Danø K. Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor. Biochemistry 1994;33:8991-8997.
10. Ploug M, Rahbeknielsen H, Ellis V et al. Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction. Biochemistry 1995;34:12524-12534.
11. Behrendt N, Rønne E, Danø K. Domain interplay in the urokinase receptor - requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains. J Biol Chem 1996;271:22885-22894.
12. Ploug M, Rønne E, Behrendt N et al. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 1991;266:1926-1933.
13. Ploug M, Plesner T, Rønne E et al. The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria. Blood 1992;79:1447-1455.
14. Ploug M, Eriksen J, Plesner T et al. A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria. Eur J Biochem 1992;208:397-404.
15. Ploug M, Kjalke M, Rønne E et al. Localization of the disulfide bonds in the NH2-terminal domain of the cellular receptor for human urokinase-type plasminogen activator. A domain structure belonging to a novel superfamily of glycolipid-anchored membrane proteins. J Biol Chem 1993;268:17539-17546.
16. Ploug M, Ellis V. Structure-function relationships in the receptor for urokinase-type plasminogen activator - comparison to other members of the Ly-6 family and snake venom alpha- neurotoxins. FEBS Lett 1994;349:163-168.
17. Todd RF, Barnathan ES, Bohuslav J et al. CD87 cluster workshop report. In: Schlossman SF, Boumsell L, Gilks W et al., eds. Leukocyte Typing V. White Cell Differentiation Antigens. Oxford, New York, Tokyo: Oxford University Press, 1995:932-939.
18. Roldan AL, Cubellis MV, Masucci MT et al. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis (published erratum appears in EMBO J 1990;9:1674). EMBO J 1990;9:467-474.
19. Møller LB, Ploug M, Blasi F. Structural requirements for glycosyl-phosphatidylinositol-anchor attachment in the cellular receptor for urokinase plasminogen activator. Eur J Biochem 1992;208:493-500.
20. Min HY, Semnani R, Mizukami IF et al. cDNA for Mo3, a monocyte activation antigen, encodes the human receptor for urokinase plasminogen activator. J Immunol 1992;148:3636-3642.
21. Casey JR, Petranka JG, Kottra J et al. The structure of the urokinase-type plasminogen activator receptor gene. Blood 1994;84:1151-1156.
22. Borglum AD, Byskov A, Ragno P et al. Assignment of the urokinase-type plasminogen activator receptor gene (PLAUR) to chromosome 19q13.1-q13.2. Am J Hum Genet 1992;50:492-497.
23. Appella E, Robinson EA, Ullrich SJ et al. The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. J Biol Chem 1987;262:4437-4440.
24. Stoppelli MP, Corti A, Soffientini A et al. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci USA 1985;82:4939-4943.
25. Ellis V, Scully MF, Kakkar VV. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J Biol Chem 1989;264:2185-2188.
26. Ellis V, Behrendt N, Danø K. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem 1991;266:12752-12758.
27. Petersen LC. Kinetics of pro-urokinase/plasminogen activation: stimulation by a template formed by the urokinase receptor bound to poly-D-lysine. Eur J Biochem 1997;245:316-323.
28. Ellis V, Danø K. Potentiation of plasminogen activation by an anti-urokinase monoclonal antibody due to ternary complex formation. A mechanistic model for receptor-mediated plasminogen activation. J Biol Chem 1993;268:4806-4813.
29. Ellis V, Ploug M, Plesner T et al. Gene expression and function of the cellular receptor for uPA (uPAR). In: Glas-Greenwalt P, ed. Fibrinolysis in Disease. Molecular and Hemovascular Aspects of Fibrinolysis. Boca Raton, Florida: CRC Press, 1995:30-42.
30. Cubellis MV, Andreasen P, Ragno P et al. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor. Proc Natl Acad Sci USA 1989;86:4828-4832.
31. Ellis V, Wun TC, Behrendt N et al. Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. J Biol Chem 1990;265:9904-9908.
32. Baker MS, Bleakley P, Woodrow GC et al. Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation. Cancer Res 1990;50:4676-4684.
33. Cubellis MV, Wun TC, Blasi F. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 1990;9:1079-1085.
34. Olson D, Pollanen J, Høyer-Hansen G et al. Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. J Biol Chem 1992;267:9129-9133.
35. Nykjær A, Petersen CM, Møller B et al. Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J Biol Chem 1992;267:14543-14546.
36. Herz J, Clouthier DE, Hammer RE. LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation (published erratum appears in Cell 1993;73:428). Cell 1992;71:411-421.
37. Kounnas MZ, Henkin J, Argraves WS et al. Low density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor mediates cellular uptake of pro-urokinase. J Biol Chem 1993;268:21862-21867.
38. Nykjær A, Kjoller L, Cohen RL et al. Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha(2)-macroglobulin receptor/low density lipoprotein receptor- related protein - evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor. J Biol Chem 1994;269:25668-25676.
39. Pöllanen J, Saksela O, Salonen EM et al. Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells. J Cell Biol 1987;104:1085-1096.
40. Pöllanen J, Hedman K, Nielsen LS et al. Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J Cell Biol 1988;106:87-95.
41. Estreicher A, Muhlhauser J, Carpentier JL et al. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol 1990;111:783-792.
42. Ossowski L. Plasminogen activator dependent pathways in the dissemination of human tumor cells in the chick embryo. Cell 1988;52:321-328.
43. Ossowski L. In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase. J Cell Biol 1988;107:2437-2445.
44. Ossowski L, Clunie G, Masucci MT et al. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J Cell Biol 1991;115:1107-1112.
45. Pyke C, Kristensen P, Ralfkiær E et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991;138:1059-1067.
46. Pyke C, Græm N, Ralfkiær E et al. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 1993;53:1911-1915.
47. Boyle MD, Chiodo VA, Lawman MJ et al. Urokinase: a chemotactic factor for polymorphonuclear leukocytes in vivo. J Immunol 1987;139:169-174.
48. Gudewicz PW, Gilboa N. Human urokinase-type plasminogen activator stimulates chemotaxis of human neutrophils. Biochem Biophys Res Commun 1987;147:1176-1181.
49. Odekon LE, Gilboa N, Del Vecchio P et al. Urokinase in conditioned medium from phorbol ester-pretreated endothelial cells promotes polymorphonuclear leukocyte migration. Circ Shock 1992;37:169-175.
50. Gyetko MR, Todd RF, Wilkinson CC et al. The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest 1994;93:1380-1387.
51. Gyetko MR, Sitrin RG, Fuller JA et al. Function of the urokinase receptor (CD87) in neutrophil chemotaxis. J Leuk Biol 1995;58:533-538.
52. Waltz DA, Chapman HA. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem 1994;269:14746-14750.
53. Wei Y, Waltz DA, Rao N et al. Identification of the urokinase receptor as all adhesion receptor for vitronectin. J Biol Chem 1994;269:32380-32388.
54. Kanse SM, Kost C, Wilhelm OG et al. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res 1996;224:344-353.
55. Xue W, Kindzelskii AL, Todd RF et al. Physical association of complement receptor type 3 and urokinase-type plasminogen activator receptor in neutrophil membranes. J Immunol 1994;152:4630-4640.
56. Bohuslav J, Horejsi V, Hansmann C et al. Urokinase plasminogen activator receptor, beta 2-integrins, and Src-kinases within a single receptor complex of human monocytes. J Exp Med 1995;181:1381-1390.
57. Kindzelskii AL, Laska ZO, Todd RF et al. Urokinase-type plasminogen activator receptor reversibly dissociates from complement receptor type 3 (alpha[M]beta[2']CD11b/CD18) during neutrophil polarization. J Immunol 1996;156:297-309.
58. Wei Y, Lukashev M, Simon DI et al. Regulation of integrin function by the urokinase receptor. Science 1996;273:1551-1555.
59. Myohänen HT, Stephens RW, Hedman K et al. Distribution and lateral mobility of the urokinase - receptor complex at the cell surface. J Histochem Cytochem 1993;41:1291-1301.
60. Høyer-Hansen G, Rønne E, Solberg H et al. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem 1992;267:18224-18229.
61. Resnati M, Guttinger M, Valcamonica S et al. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 1996;15:1572-1582.
62. Sitrin RG, Todd RF, Petty HR et al. The urokinase receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes. J Clin Invest 1996;97:1942-1951.
63. Simon DI, Rao NK, Xu H et al. Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells. Blood 1996;88:3185-3194.
64. Dumler I, Petri T, Schleuning WD. Interaction of urokinase-type plasminogen activator (u-PA) with its cellular receptor (u-PAR) induces phosphorylation on tyrosine of a 38 kDa protein. FEBS Lett 1993;322:37-40.
65. Cao DR, Mizukami IF, Garniwagner B et al. Human urokinase-type plasminogen activator primes neutrophils for superoxide anion release - possible roles of complement receptor type 3 and calcium. J Immunol 1995;154:1817-1829.
66. Liesveld J, Winslow JM, Frediani KE et al. Expression of integrins and examination of their adhesive function in normal and leukemic hematopoietic cells. Blood 1993;81:112-121.
67. Plesner T, Ralfkiær E, Wittrup M et al. Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. Am J Clin Pathol 1994;102:835-841.
68. Todd RF, Alvarez PA, Brott DA et al. Bacterial lipopolysaccharide, phorbol myristate acetate, and muramyl dipeptide stimulate the expression of a human monocyte surface antigen, Mo3e. J Immunol 1985;135:3869-3877.
69. Todd RF, Bury MJ, Alvarez PA et al. Regulation of human monocyte surface antigen expression. I. Up-modulation of Mo3e antigen expression on U-937 and HL-60 cells stimulated by pharmacologic activators of protein kinase C. Blood 1986;68:1154-1161.
70. Liu DY, Ree JY, Trochelman RD et al. Identification of a human monocyte antigen (Mo3e) associated with cellular activation and lymphokine responsiveness. Eur J Immunol 1989;19:721-727.
71. Todd RF, Adams MD, Rogers CE et al. Evidence for an intracellular pool of a migration inhibitory factor-associated, activation antigen of human mononuclear phagocytes, Mo3e. J Immunol 1988;140:1095-1100.
72. Liu DY, Todd RF. A monoclonal antibody specific for a monocyte-macrophage membrane component blocks the human monocyte response to migration inhibitory factor. J Immunol 1986;137:448-455.
73. Todd RF, Bury MJ, Liu DY. Expression of an activation antigen, Mo3e, associated with the cellular response to migration inhibitory factor by HL-60 promyelocytes under-going monocyte-macrophage differentiation. J Leuk Biol 1987;41:492-499.
74. Miles LA, Plow EF. Receptor mediated binding of the fibrinolytic components, plasminogen and urokinase, to peripheral blood cells. Thromb Haemost 1987;58:936-942.
75. Nykjær A, Petersen CM, Moller B et al. Identification and characterization of urokinase receptors in natural killer cells and T-cell-derived lymphokine activated killer cells. FEBS Lett 1992;300:13-17.
76. Nykjær A, Møller B, Todd RF et al. Urokinase receptor - an activation antigen in human T-lymphocytes. J Immunol 1994;152:505-516.
77. Bianchi E, Ferrero E, Fazioli F et al. Integrin-dependent induction of functional urokinase receptors in primary T lymphocytes. J Clin Invest 1996;98:1133-1141.
78. Kramer MD, Spring H, Todd RF et al. Urokinase-type plasminogen activator enhances invasion of human T cells (Jurkat) into a fibrin matrix. J Leuk Biol 1994;56:110-116.
79. Plesner T, Ploug M, Ellis V et al. The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils. Blood 1994;83:808-815.
80. Tapiovaara H, Alitalo R, Stephens R et al. Abundant urokinase activity on the surface of mononuclear cells from blood and bone marrow of acute leukemia patients. Blood 1993;82:914-919.
81. Rosse WF, Ware RE. The molecular basis of paroxysmal nocturnal hemoglobinuria. Blood 1995;86:3277-3286.
82. Plesner T, Birgens H, Hansen NE. Paroxysmal nocturnal hemoglobinuria. In: Seghatchian MJ, Samama MM, Hecker SP, eds. Pathogenesis and Clinical Manifestations of Thrombosis. Boca Raton, Florida: CRC Press, Inc., 1995:285-292
83. Takeda J, Miyata T, Kawagoe K et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993;73:703-711.
84. Miyata T, Takeda J, Iida Y et al. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science 1993;259:1318-1320.
85. Plesner T, Hansen NE, Carlsen K. Estimation of PI-bound proteins on blood cells from PNH patients by quantitative flow cytometry. Br J Haematol 1990;75:585-590.
86. Pedersen TL, Yong K, Pedersen JO et al. Impaired migration in vitro of neutrophils from patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 1996;95:45-51.
87. Heiple JM, Ossowski L. Human neutrophil plasminogen activator is localized in specific granules and is translocated to the cell surface by exocytosis. J Exp Med 1986;164:826-840.
88. Grøndahl-Hansen J, Kirkeby LT, Ralfkiær E et al. Urokinase-type plasminogen activator in endothelial cells during acute inflammation of the appendix. Am J Pathol 1989;135:631-636.
89. Rønne E, Pappot H, Gr¢ndahl-Hansen J et al. The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 1995;89:576-581.
90. Henry RL. Leukocytes and thrombosis. Thromb Diath Haemorrh 1965;13:35-46.
91. Gans H. Fibrinolytic properties of proteases derived from human, dog and rabbit leukocytes. Thromb Diath Haemorrh 1963;10:379-389.
92. Riddle JM, Barnhart MI. Ultrastructural study of fibrin dissolution via emigrated polymorphonuclear neutrophils. Am J Pathol 1964;45:805-823.
93. Moroz LA, Sniderman AD, Marpole DG. Leukocyte-plasma interaction in fibrinolysis. A new dimension in the action of urokinase. N Engl J Med 1979;301:1100-1104.
94. Murphy Ullrich JE, Mosher DF. Localization of thrombospondin in clots formed in situ. Blood 1985;66:1098-1104.
95. Herijgers N, Vettel U, Schaefer B et al. Cell surface-bound urokinase-type plasminogen activator facilitates infiltration of freshly isolated granulocytes into a fibrin matrix. Immunobiology 1995;194:363-375.
96. Brunner G, Gabrilove J, Rifkin DB et al. Phospholipase C release of basic fibroblast growth factor from human bone marrow cultures as a biologically active complex with a phosphatidylinositol-anchored heparan sulfate proteoglycan. J Cell Biol 1991;114:1275-1283.
97. Brunner G, Metz CN, Nguyen H et al. An endogenous glycosylphosphatidylinositol-specific phospholipase-D releases basic fibroblast growth factor - heparan sulfate proteoglycan complexes from human bone marrow cultures. Blood 1994;83:2115-2125.
98. Falcone DJ, McCaffrey TA, Haimovitz Friedman A et al. Macrophage and foam cell release of matrix-bound growth factors. Role of plasminogen activation. J Biol Chem 1993;268:11951-11958.
99. Blasi F, Behrendt N, Cubellis MV et al. The urokinase receptor and regulation of cell surface plasminogen activation. Cell Differ Dev 1990;32:247-253.
100. Odekon LE, Blasi F, Rifkin DB. Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-beta to TGF- beta. J Cell Physiol 1994;158:398-407.
101. Naldini L, Tamagnone L, Vigna E et al. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J 1992;11:4825-4833.
102. Hannocks MJ, Oliver L, Gabrilove JL et al. Regulation of proteolytic activity in human bone marrow stromal cells by basic fibroblast growth factor, interleukin-1, and transforming growth factor beta. Blood 1992;79:1178-1184.
103. Sitrin RG, Todd RF, Mizukami IF et al. Cytokine-specific regulation of urokinase receptor (CD87) expression by U937 mononuclear phagocytes. Blood 1994;84:1268-1275.
104. Gyetko MR. Shollenberger SB, Sitrin RG. Urokinase expression in mononuclear phagocytes: cytokine-specific modulation by interferon-gamma and tumor necrosis factor-alpha. J Leuk Biol 1992;51:256-263.
105. Hamilton JA, Vairo G, Knight KR et al. Activation and proliferation signals in murine macrophages. Biochemical signals controlling the regulation of macrophage urokinase-type plasminogen activator activity by colony-stimulating factors and other agents. Blood 1991;77:616-627.
106. Hart PH, Vitti GF, Burgess DR et al. Activation of human monocytes by granulocyte-macrophage colony-stimulating factor: increased urokinase-type plasminogen activator activity. Blood 1991;77:841-848.
107. Hamilton JA, Whitty GA, Stanton H et al. Effects of macrophage-colony stimulating factor on human monocytes - induction of expression of urokinase-type plasminogen activator, but not of secreted prostaglandin - E2, interleukin-6, interleukin-1, or tumor necrosis factor- alpha. J Leuk Biol 1993;53:707-714.
108. Hamilton JA, Whitty GA, Stanton H et al. Macrophage colony-stimulating factor and granulocyte-macrophage colony-stimulating factor stimulate the synthesis of plasminogen-activator inhibitors by human monocytes. Blood 1993;82:3616-3621.
109. Gyetko MR, Wilkinson CC, Sitrin RG. Monocyte urokinase expression - modulation by interleukins. J Leuk Biol 1993;53:598-601.
110. Hart PH, Burgess DR, Vitti GF et al. Interleukin-4 stimulates human monocytes to produce tissue-type plasminogen activator. Blood 1989;74:1222-1225.
111. Hamilton JA, Whitty GA, Wojta J et al. Regulation of plasminogen activator inhibitor-1 levels in human monocytes. Cell Immunol 1993;152:7-17.
112. Falcone DJ, McCaffrey TA, Haimovitz Friedman A et al. Transforming growth factor-beta 1 stimulates macrophage urokinase expression and release of matrix-bound basic fibroblast growth factor. J Cell Physiol 1993;155:595-605.
113. Hamilton JA, Whitty GA, Last K et al. Interleukin-4 suppresses plasminogen activator inhibitor-2 formation in stimulated human monocytes. Blood 1992;80:121-125.